DelveInsight’s “Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology and the FSGS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Focal Segmental Glomerulosclerosis Market with DelveInsight’s In-Depth Report @ Focal Segmental Glomerulosclerosis Market Size
Key Takeaways from the Focal Segmental Glomerulosclerosis Market Report
- In December 2024:- Astellas Pharma Global Development, Inc.- The purpose of this study was to assess the efficacy of the bleselumab regimen (basiliximab induction, tacrolimus, steroids and bleselumab) compared with the Standard of Care (SOC) regimen (basiliximab induction, tacrolimus, steroids and mycophenolate mofetil [MMF]) in the prevention of recurrent Focal Segmental Glomerulosclerosis (rFSGS) defined as nephrotic range proteinuria with protein-creatinine ratio (≥ 3.0 g/g) through 3 months post-transplant. Death, graft loss or lost to follow-up were imputed as rFSGS.
- In December 2024:- Sanofi- A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, and Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD).
- The overall count of individuals diagnosed with Focal Segmental Glomerulosclerosis in the United States was approximately 26 million in 2022, and it is expected to increase at an estimated CAGR throughout the study period (2020-2034).
- Among the 7MM, Japan accounted for the highest number of Focal Segmental Glomerulosclerosis diagnosed cases of around 8 million cases in 2022. Forecasts indicate a projected increase in the cases during the period (2023-2034).
- Among EU4 and the UK, Germany had the highest Focal Segmental Glomerulosclerosis diagnosed prevalent population, with about 5 million cases, followed by France and Italy in 2022. On the other hand, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
- In 2022, DelveInsight’s analysis of Focal Segmental Glomerulosclerosis gender-specific diagnosed prevalent cases within the 7MM indicated an approximate distribution of 40% in males and 60% in females.
- The leading Focal Segmental Glomerulosclerosis Companies such as Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company and others.
- Promising Focal Segmental Glomerulosclerosis Therapies such as DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others.
Stay ahead in the Focal Segmental Glomerulosclerosis Therapeutics Market with DelveInsight’s Strategic Report @ Focal Segmental Glomerulosclerosis Market Outlook
Focal Segmental Glomerulosclerosis Epidemiology Segmentation in the 7MM
- Total Focal Segmental Glomerulosclerosis Diagnosed Prevalent Cases
- Focal Segmental Glomerulosclerosis Gender-specific Cases
- Diagnosed Prevalent Cases
- Focal Segmental Glomerulosclerosis Age-specific Diagnosed Prevalent Cases
- Focal Segmental Glomerulosclerosis Comorbodity-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis Epidemiology trends @ Focal Segmental Glomerulosclerosis Prevalence
Focal Segmental Glomerulosclerosis Marketed Drugs
- LEQVIO (Inclisiran): Novartis Pharmaceuticals Corporation
LEQVIO (Inclisiran) is a sole small-interfering RNA (siRNA) therapy designed to lower LDL cholesterol. The drug utilizes the RNA interference mechanism and directs the catalytic breakdown of mRNA for PCSK9. This increases LDL-C receptor recycling and expression on the hepatocyte cell surface, which increases LDL-C uptake and lowers LDL-C levels in the circulation. LEQVIO, the sole approved FSGS treatment in United States and Europe with an active patent, dominates the FSGS treatment landscape, immune to biosimilar competition.
Focal Segmental Glomerulosclerosis Emerging Drugs
- Olpasiran (AMG 890): Amgen Inc.
Olpasiran (AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a). It is being investigated for treating FSGS; the drug is administered subcutaneously as a solution. Olpasiran is currently in Phase III clinical trial in participants with FSGS and elevated lipoprotein (a). The absence of approved alternatives highlights the potential for Olpasiran to contribute significantly to the expansion of the FSGS treatment market.
Focal Segmental Glomerulosclerosis Market Outlook
Focal Segmental Glomerulosclerosis (FSGS), encompassing diverse conditions like CAD, PAD, and cerebrovascular disease, all rooted in atherosclerosis. FSGS is influenced by genetic predisposition, lifestyle factors, and comorbidities. Strategies vary depending on the severity of the disease, aiming to curb FSGS. Treatment for FSGS starts with a change in lifestyle that includes stress management, regular exercise, dietary adjustments, and quitting smoking. Their potential to supplement pharmaceutical therapies and effectively lower cardiovascular risk factors is highlighted by a thorough examination of their influence on patient outcomes.
Get In-Depth Knowledge on Focal Segmental Glomerulosclerosis Market Trends and Forecasts with DelveInsight @ Focal Segmental Glomerulosclerosis Treatment Market
Focal Segmental Glomerulosclerosis Treatment Market
As the Focal Segmental Glomerulosclerosis Treatment Market Landscape evolves, the emergence of Olpasiran in a Phase III trial brings hope for a targeted therapeutic option. The projected introduction of Olpasiran for FSGS is anticipated to propel the overall FSGS market in the 7MM, potentially reaching nearly USD 837 million by 2034.
Scope of the Focal Segmental Glomerulosclerosis Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Focal Segmental Glomerulosclerosis Companies- Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, Pfizer, Chinook Therapeutics, Inc., Genentech, Complexa, Imara, ZyVersa, Boehringer Ingelheim, Eli Lilly and Company and others.
- Focal Segmental Glomerulosclerosis Therapies- DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others.
- Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
- Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
- Focal Segmental Glomerulosclerosis Unmet Needs, KOL’s views, Analyst’s views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Focal Segmental Glomerulosclerosis Market Report @ Focal Segmental Glomerulosclerosis Market Drivers and Barriers
Table of Content
1 Key Insights
2 Report Introduction
3 Focal Segmental Glomerulosclerosis (FSGS) Market Overview by Therapies
4 Methodology of FSGS Epidemiology and Market
5 Executive Summary of Focal Segmental Glomerulosclerosis (FSGS)
6 Key Events
7 Disease Background and Overview: FSGS
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 FSGS: Market Analysis
13 Key Opinion Leaders’ Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services